Free Newsletter
SPOTLIGHT: Exubera pain grows worse
The pain of dismal Exubera sales is spreading. West Pharmaceutical Services, which makes 60 percent of the inhaler used to deliver the insulin spray, told the Securities and Exchange Commission that it's cutting production in response to lower-than-expected turnover. The highly anticipated Pfizer product only sold $4 million worth during the second quarter. "We expect Pfizer's high inventory levels and slower-than-expected demand will affect our fourth-quarter 2007 and full-year 2008 sales," according to documents filed with the SEC. The filing goes on to state that West has cut production of the inhaler to one shift per day. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: